Puma Biotechnology (PBYI) Return on Capital Employed (2012 - 2026)

Puma Biotechnology's Return on Capital Employed history runs 15 years deep, the most recent figure standing at 20.37% for Q1 2026.

• Quarterly Return on Capital Employed fell 1117.0% year-over-year to 20.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.37% (down 1117.0% YoY) and the FY2025 annual result came in at 27.93%, up 331.0% from the prior year.
• Return on Capital Employed was 20.37% for Q1 2026 at Puma Biotechnology, down from 29.07% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 39.56% in Q2 2025 and bottomed at 14.05% in Q1 2022.
• A 5-year average of 20.76% and a median of 20.68% in 2023 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2022 — Return on Capital Employed sank 1764 bps — and 2023, when it soared 3196 bps.
• Puma Biotechnology's Return on Capital Employed stood at 17.84% in 2022, then surged by 55 bps to 27.74% in 2023, then slipped by 8 bps to 25.61% in 2024, then rose by 13 bps to 29.07% in 2025, then decreased by 30 bps to 20.37% in 2026.
• Business Quant data shows PBYI's Return on Capital Employed at 20.37% in Q1 2026, 29.07% in Q4 2025, and 28.89% in Q3 2025.